

March 28, 2008

TOKIO MARINE CAPITAL

Acquisition of shares of Calonal

TOKIO MARINE CAPITAL CO., LTD. today announced that it reached an agreement to acquire shares of Calonal Co., Ltd., a superior pharmaceutical company renowned for its acetaminophen-based antifebrile and dental anesthesia drugs, with Polaris Principal Finance Co., Ltd. and AIG Japan Capital Investment Co., Ltd.

Overview of Calonal

(1) Company name	Holding Company: Calonal Co., Ltd. Business subsidiaries: Showa Yakuhin Kako Co., Ltd. SYK Seto Co., Ltd.
(2) Business	Manufacturing, Sales and Trading of Medicines, Medical equipments, reagent and other drugs/chemicals
(3) Main products	Medical drugs: "Calonal": Acetaminophen-based antifebrile "Aphtasolon": Drug for canker sore Dental drugs: "ORA": Dental anesthesia injection drug "Peliofeel": Drug for periodontal treatment
(4) Established	July 1948
(5) Head office address	Kyobashi, Chuo-ku, Tokyo, Japan
(6) Representative	President and Representative director: Izumi Nomura
(7) Number of Employees	238 (as of December 31, 2007, consolidated)
(8) Capital	4,775 million JPY (as of December 31, 2007, consolidated)
(9) Sales	8,793 million JPY (Fiscal Year 2007, consolidated)

Contact

Shunichiro NAKAGAWA, Partner, TOKIO MARINE CAPITAL CO., LTD.

Phone: +81-3-5223-3516 FAX: +81-3-5223-3547